Information Provided By: 
Fly News Breaks for September 21, 2017
IONS, ALNY
Sep 21, 2017 | 04:59 EDT
Barclays analyst Gena Wang raised her price target for Alnylam Pharmaceuticals (ALNY) to $127 citing the company's positive topline data from the Apollo Phase study in TTR amyloidosis. The analyst increased patisiran's probability of success to 95% from 85% and reiterates an Overweight rating on the shares. Wang also decreased her price target on Equal Weight-rated Ionis Pharmaceuticals (IONS) to $52 from $55 saying Alnylam's data suggest strong competition for inotersen.
News For ALNY;IONS From the Last 2 Days
ALNY
Apr 23, 2024 | 07:17 EDT
ProQR Therapeutics (PRQR) announced the Annual General Meeting, AGM, of Shareholders will take place on Wednesday, May 22, 2024 at the offices of Allen & Overy LLP, in Amsterdam, the Netherlands. As part of the AGM, Martin Maier, PhD, is nominated for appointment as a non-executive Board Member for a period of four years. Dr. Maier is Senior Vice President Research heading the Oncology group at Alnylam Pharmaceuticals (ALNY).
